| Acute encephalopathy | | Asparaginase | | 5-Azacytidine | | BCNU (IA or HD) | | Cisplatin | | Corticosteroids | | Cytarabine (HD) | | Etoposide | | Fludarabine | | FU | | Glucocorticoids | | Hexamethylmelamine | | Ifosfamide | | Interferons | | Interleukin-1 and -2 | | Methotrexate | | Mitomycin C | | Nelarabine | | Nitrogen mustard | | Pentostatin | | Procarbazine | | Sunitinib | | Tamoxifen | | Thiotepa (HD) | | Tumor necrosis factor | | Vinca alkaloids | | Headaches | | Asparaginase | | Corticosteroids | | Cytarabine (IT) | | Etoposide | | Fludarabine | | Hexamethylmelamine | | Interferons | | Interleukins 1, 2, and 4 | | Mechlorethamine | | Methotrexate (IT) | | Nelarabine | | Retinoic acid | | Tamoxifen | | Temozolomide | | Thiotepa (IT) | | | Vasculopathies and "strokes" | | Aflibercept | | Antiangiogenic tyrosine kinase inhibitors (axitinib, cabozantinib, lenvatinib, pazopanib, ponatinib, regorafenib, sorafenib, sunitinib, vandetanib) | | Asparaginase | | BCNU (IA) | | Bevacizumab | | Cisplatin (IA) | | Doxorubicin | | Estramustine | | Methotrexate | | Ramucirumab | | Seizures | | Asparaginase | | BCNU | | Busulfan (HD) | | Cisplatin | | Cytarabine (HD) | | Dacarbazine | | Enzalutamide | | Etoposide | | FU | | Gemcitabine | | Ifosfamide | | Interferon | | Interleukin-2 | | Methotrexate | | Nelarabine | | Nitrogen mustard | | Pentostatin | | Teniposide | | Vinca alkaloids | | Retinal toxicity | | Alkylating agents (carboplatin, cisplatin, oxaliplatin, procarbazine) | | Antimetabolites (capecitabine, cytarabine, fludarabine, methotrexate) | | BRAF inhibitors (dabrafenib, vemurafenib) | | Docetaxel, paclitaxel | | Ipilimumab | | MEK inhibitors (trametinib) | | Tamoxifen, toremifene | | Vincristine | | Uveitis | | Ipilimumab | | Nivolumab | | Rituximab | | Vemurafenib | | Aseptic meningitis | | Cytarabine (IT) | | Methotrexate (IT) | | Dementia | | BCNU (IA and HD) | | Cytarabine | | Fludarabine | | Interferon alfa | | Methotrexate | | | Myelopathy | | Cytarabine (IT) | | Methotrexate (IT) | | Thiotepa (IT) | | Cranial neuropathy | | BCNU (IA) (ototoxicity) | | Cisplatin (ototoxicity, optic neuropathy) | | Crizotinib (optic neuropathy) | | Docetaxel, paclitaxel (optic neuropathy) | | Imatinib (optic neuropathy) | | Vincristine (extraocular palsies, optic neuropathy) | | Neuropathy | | 5-Azacytidine | | Bortezomib | | Carboplatin | | Cisplatin | | Cytarabine (including Guillain-Barré syndrome) | | Eribulin | | Etoposide | | FU | | Gemcitabine | | Hexamethylmelamine | | Ifosfamide | | Interferon alfa | | Ipilimumab | | Ivosidenib (Guillain-Barré syndrome) | | Ixabepilone | | Lenalidomide | | Nelarabine (Guillain-Barré syndrome) | | Paclitaxel | | Procarbazine | | Purine analogs (cladribine, fludarabine, nelarabine, pentostatin) | | Suramin | | Teniposide (VM-26) | | Thalidomide | | Tumor necrosis factor | | Vinca alkaloids | | Acute cerebellar syndrome | | Capecitabine | | Cytarabine (HD) | | FU | | Hexamethylmelamine | | Procarbazine | | Vinca alkaloids | |
